Although hypnotherapy did not improve quality of life, psychological symptoms, cognition, self-efficacy, or irritable bowel syndrome (IBS) symptoms significantly more than an educational support program, it may provide relief to patients by changing
Patients with irritable bowel syndrome (IBS) who had been randomized to receive remote cognitive behavioral therapy (CBT) had lower symptom severity scores than those who had received usual care, according to follow-up data from a British trial.
A case-control study found that patients who developed colon cancer, particularly in the proximal colon, were more likely to have taken antibiotics, whereas antibiotic use was not associated with increased risk of rectal cancer.
In this Swedish case-control study, any previous GI infection and previous bacterial, parasitic, and viral GI infection were associated with higher risk for inflammatory bowel disease (IBD) versus controls.
In 19 randomized controlled trials of 6,261 hospitalized patients on antibiotics, the incidence of C. difficile was 1.6% among patients taking probiotics compared to 3.9% in controls.
A retrospective trial showed no increase in new corticosteroid therapy or disease-related hospitalization or surgery among patients who discontinued 5-aminosalycilate (5-ASA) therapy when initiating an anti-tumor necrosis factor (anti-TNF) agent.
The therapy should be considered in patients with genotype 1 infection who are treatment-naive, do not have cirrhosis, and have a pretreatment viral load below 6,000,000 IU/mL, a study found.
Clarithromycin triple therapy should be used for first-line treatment of Helicobacter pylori infection only in patients with no history of macrolide exposure who live in areas where H. pylori resistance to clarithromycin is known to be low, among
Oral sulfasalazine, diazo-bonded 5-aminosalicylates (5-ASAs), mesalazine, controlled ileal-release budesonide, and budesonide multimatrix, alone or in combination with rectal 5-ASA therapy, were assessed for comparative efficacy and tolerability.
In a meta-analysis of 22 studies in patients with nonalcoholic fatty liver disease (NAFLD), weight loss interventions were associated with improvements in alanine aminotransferase level, liver steatosis, histologic NAFLD activity score, and